| 000 | 01079cam a2200205 4500500 | ||
|---|---|---|---|
| 005 | 20251012013219.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aFrances, Pierre _eauthor |
| 700 | 1 | 0 |
_a Osst, Peebles _eauthor |
| 700 | 1 | 0 |
_a Gaubert, Robert _eauthor |
| 700 | 1 | 0 |
_a Comte, Ulysse _eauthor |
| 700 | 1 | 0 |
_a Nisus, Noémi _eauthor |
| 245 | 0 | 0 | _aA misused psychoactive substance: Captagon |
| 260 | _c2025. | ||
| 500 | _a19 | ||
| 520 | _aCaptagon is a drug marketed in 1960 to treat attention deficit disorder and narcolepsy. The effects of this drug, which generates aggression, performance enhancement, and insomnia, were quickly taken into account by terrorists for their own use. At the same time, the addictive effects of this drug required clinicians to provide appropriate treatment, by acting both on the psychiatric disorders induced and on the malnutrition caused by taking Captagon. | ||
| 786 | 0 | _nMédecine | 21 | 6 | 2025-08-25 | p. 259-262 | 1777-2044 | |
| 856 | 4 | 1 | _uhttps://shs.cairn.info/journal-medecine-2025-6-page-259?lang=en&redirect-ssocas=7080 |
| 999 |
_c1528750 _d1528750 |
||